Citizens JMP raised the firm’s price target on Halozyme (HALO) to $92 from $91 and keeps an Outperform rating on the shares. Halozyme reported a strong quarter driven by indication and global expansion of ENHANZE partnered products, the analyst tells investors in a research note. The firm expects Halozyme to achieve 2026 EBITDA of more than $1B, a milestone it would reach a year ahead of prior long-term guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Therapeutics Reports Strong Q3 2025 Results
- Halozyme’s Strong Q3 Performance and Promising Future Drive Buy Rating
- Halozyme Raises 2025 Guidance After Strong Q3 Results
- Halozyme raises 2025 non-GAAP EPS view to $6.10-$6.50 from $6.00-$6.40
- Halozyme reports Q3 non-GAAP EPS $1.72, consensus $1.61